Products for Research Use Only
RegisterLogin

Cyclo (-RGDfK)

CAT: 0804-HY-P0023-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P0023-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cyclo (-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo (-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[2].
CAS Number
161552-03-0
UNSPSC
12352209
Hazard Statement
H302, H315, H319, H335
Target
Integrin
Type
Peptides
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Cyclo_-RGDfK_.html
Purity
99.83
Solubility
DMSO : 83.33 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
Smiles
O=C([C@H](CCCCN)NC([C@@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC(CN2)=O)=O)=O)N[C@@H](CCCNC(N)=N)C2=O
Molecular Formula
C27H41N9O7
Molecular Weight
603.67
Precautions
H302, H315, H319, H335
References & Citations
[1]Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68) Ga-NOPO-c (RGDfK) . Mol Pharm. 2014 May 5;11 (5) :1687-95.|[2]Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66) Ga-DOTA-E (c (RGDfK) ) 2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42 (2) :109-14.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
αvβ3
Citation 01
ACS Appl Mater Interfaces. 2019 Jul 31;11 (30) :26648-26663. |Acta Biomater. 2021 May:126:183-198.|Adv Healthc Mater. 2021 Jul;10 (13) :e2100304.|Adv Sci (Weinh) . 2025 Oct 30:e01602.|Antioxidants (Basel) . 2024 Nov 1;13 (11) :1339.|Bioact Mater. 2021 Jan 7;6 (7) :2039-2057.|Biochem Biophys Res Commun. 2023 Sep 3:671:124-131.|Biochim Biophys Acta Mol Basis Dis. 2025 Mar 31;1871 (5) :167814.|bioRxiv. 2024 July 13.|bioRxiv. 2025 April 01.|Bone Res. 2024 Aug 28;12 (1) :49.|Drug Deliv Transl Res. 2024 Oct;14 (10) :2629-2641.|Engineering. 8 October 2020.|Free Radic Biol Med. 2024 Dec 9:227:296-311.|Heliyon. 2024 Jul 2;10 (13) :e34006.|J Extracell Vesicles. 2025 Aug;14 (8) :e70146.|J Nanobiotechnology. 2024 Sep 1;22 (1) :528.|Mater Today Nano. 2023 Dec:24:100432.|Mol Biol Rep. 2025 Feb 5;52 (1) :205.|Mol Ther Nucleic Acids. 2021 Jan 9;23:797-810.|Res Sq. 2024 Aug 07.|ACS Biomater Sci Eng. 2023 May 8;9 (5) :2524-2533.|Cell Mol Gastroenterol Hepatol. 2025 May 29:101548.|Int Immunopharmacol. 2025 May 26:159:114947.

Related Products

CatalogName
HY-100563A-01Cyclo (RGDyK)
HY-100563ARCyclo (RGDyK) (Standard)
HY-100563-01Cyclo (RGDyK) (trifluoroacetate)
HY-100563RCyclo (RGDyK) (trifluoroacetate) (Standard)
HY-P5098-01E (c (RGDfK) ) 2
HY-P0031-01Cyclo (RADfK)
HY-P10222Cyclo (CRLLIF)
HY-P10426-01Cyclo (CLLFVY)
HY-P5840-01Cyclo (RGDyC)
HY-P1676-01Cyclo (RLsKDK)

Alternative Products

CatalogName
A8164-25Cyclo (-RGDfK)
B2363-5Cyclo（RGDfK）
GTR19157085-01Cyclo (RGDfK)
MBS3611707-01Cyclo(RGDfK)
BUP01160-01Cyclo (-RGDfK) TFA
GTR19150470-01DBCO-cyclo (RGDfK)
GTR19034639-01Cyclo (RGDfK (Mal) )

Popular Products